GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Mesa Laboratories Inc (FRA:MLI) » Definitions » Cash And Cash Equivalents

Mesa Laboratories (FRA:MLI) Cash And Cash Equivalents : €25.9 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mesa Laboratories Cash And Cash Equivalents?

Mesa Laboratories's quarterly cash and cash equivalents increased from Jun. 2023 (€29.88 Mil) to Sep. 2023 (€33.37 Mil) but then stayed the same from Sep. 2023 (€33.37 Mil) to Dec. 2023 (€25.88 Mil).

Mesa Laboratories's annual cash and cash equivalents declined from Mar. 2021 (€221.65 Mil) to Mar. 2022 (€44.81 Mil) and declined from Mar. 2022 (€44.81 Mil) to Mar. 2023 (€30.74 Mil).


Mesa Laboratories Cash And Cash Equivalents Historical Data

The historical data trend for Mesa Laboratories's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesa Laboratories Cash And Cash Equivalents Chart

Mesa Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.01 73.65 221.65 44.81 30.74

Mesa Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.64 30.74 29.88 33.37 25.88

Mesa Laboratories Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Mesa Laboratories  (FRA:MLI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Mesa Laboratories Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mesa Laboratories's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesa Laboratories (FRA:MLI) Business Description

Traded in Other Exchanges
Address
12100 West Sixth Avenue, Lakewood, CO, USA, 80228
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators. It also provides testing and laboratory services, mainly to the dental industry; Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions; Calibration Solutions division develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes; and Clinical Genomics. Its geographical segments include United States and Foreign.